How does BioMate AI compare to Claude Science for bioinformatics research?

BioMate AI is a full execution platform: it routes requests to 4,000+ indexed bioinformatics workflows, runs them on AWS Batch compute, queries 60+ live databases at analysis time, and delivers QC-gated reports with auto-remediation. Claude Science is a reasoning assistant that can help interpret biology and suggest analysis approaches but does not execute pipelines, provision compute, or integrate live databases. For researchers who need to run actual RNA-seq, GWAS, ADMET, or PBPK analyses and receive auditable outputs, BioMate AI and Claude Science serve different roles.

Which AI platform has the highest score on BixBench?

As of April 2026, BioMate AI achieved 92.7% on BixBench v36 (N=205 bioinformatics agent tasks), the highest published score on this benchmark. BixBench was created by the BioMate team (Xu et al., 2025) to evaluate AI systems on realistic bioinformatics tasks including differential expression, variant calling, and pathway analysis.

What is BiomniEval1 and how do AI biomedical platforms score on it?

BiomniEval1 is a comprehensive biomedical AI evaluation benchmark covering 20 tasks across genomics, proteomics, drug discovery, and clinical reasoning. As of the published leaderboard: BioMate AI scores approximately 68–69%, outperforming Biomni (65.9%). The benchmark was created by the Biomni research team and is publicly available.

Can GPT-5.5 or Claude Science run genomics pipelines?

GPT-5.5 and Claude Science are large language model assistants — they can describe workflows, explain methods, and help interpret results, but they do not execute bioinformatics pipelines. They have no access to AWS Batch compute, no integration with Nextflow or nf-core pipelines, and do not connect to live biological databases like Ensembl, gnomAD, or ChEMBL at query time. BioMate AI provides actual pipeline execution with real compute and live data access.

What live databases does BioMate AI query during an analysis?

BioMate AI queries 60+ live databases at analysis time — not cached snapshots. These include: Protein & Structure (UniProt, PDB, AlphaFold DB, InterPro), Genomics & Variant (Ensembl, gnomAD, ClinVar, COSMIC, OMIM, GWAS Catalog), Transcriptomics (GEO, SRA, TCGA, cBioPortal), Chemistry (ChEMBL, PubChem, DrugBank, BindingDB), Pathways (KEGG, Reactome, Gene Ontology, STRING-db), and Literature (PubMed, bioRxiv, ClinicalTrials.gov, FDA labels).

How does BioMate AI score on LABBench CloningScenarios?

BioMate AI achieved 93.9% on the LABBench CloningScenarios sub-benchmark (33 molecular cloning MCQ problems, BioMate internal evaluation, April 2026), compared to Claude 3.5 Sonnet's 60% published in the original Jansen et al. (2025) paper.

Platform Comparison · July 2026

BioMate AI Claude Science Biomni Robin & Finch GPT-5.5 · Rosalind 10 min read

BioMate AI vs. Claude Science vs. Biomni vs. Robin & Finch vs. GPT-5.5

A comparison of AI platforms for biomedical research — capabilities, benchmarks, and intended use.

Five distinct platforms for AI-assisted biomedical research launched within twelve months of each other. Each takes a different approach: execution infrastructure, research workbench, autonomous agent, discovery system, or foundation model. This comparison covers what each actually does, where each performs, and how they differ.

The Five Platforms at a Glance

BioMate AI AI Research & Execution Platform

Natural-language interface to 4,000+ indexed workflows, 60+ live scientific databases, and literature synthesis. Executes analyses on AWS Batch, enforces QC gates, and delivers audit-ready outputs including IND sections and CRO packages.

Commercial · Free tier available

Anthropic · June 2026 Claude Science

AI research workbench with specialists for genomics, scRNA-seq, proteomics, and cheminformatics; connects to 60+ scientific databases; generates figures and manuscripts.

Beta · Grant program open

Stanford SNAP · 2025 Biomni

General-purpose biomedical AI agent using ReAct-style reasoning over LLMs, retrieval, and tool calls across diverse biomedical task types.

Open-source · Research

Future House · Nature 2026 Robin + Finch

Multi-agent system for autonomous drug discovery. Crow/Falcon handle literature retrieval via PaperQA2; Finch runs RNA-seq and flow cytometry analysis in Docker.

Nonprofit · Research / Open-source

OpenAI · 2025–2026 GPT-5.5 / Rosalind

Foundation model family for life sciences. GPT-Rosalind specializes in drug discovery, genomics, and protein reasoning. Strong general reasoning; no built-in execution layer.

Commercial API · ChatGPT for Healthcare

Benchmark Evaluation

The benchmarks below use published standardized datasets where multiple systems have been evaluated and scores are verifiable. Each section includes a description of the benchmark, citation, task count, and scoring scale.

BixBench — agentic computational biology (FutureHouse + ScienceMachine, 2025)

What it measures: 54 capsules / 205 tasks derived from published computational biology analyses. Agents must reproduce the original analytical conclusions (gene lists, statistical outputs, structural comparisons) from raw data. Open-answer, LLM-judge graded. Scale: 0–100%, task-level pass/fail aggregated. Citation: FutureHouse BixBench leaderboard (llm-stats.com/benchmarks/bixbench); saturation paper bioRxiv 2026.04.28.721523.

BioMate v36

92.7%

Biomni Lab Stanford SNAP

88.7%

GPT-5.5 Raw, no skills

80.5%

GPT-Rosalind OpenAI

75.1%

BiomniEval1 — biomedical knowledge and reasoning (Stanford SNAP, 2025)

What it measures: 223 tasks across 5 biomedical subtasks: GWAS causal gene identification (Open Targets API), GWAS variant association (GWAS Catalog), rare disease diagnosis (OMIM/ClinVar), patient gene prioritization, and CRISPR screen hit identification. Scale: Exact-match accuracy per subtask; overall = mean across all 223 tasks. Citation: Biomni preprint, bioRxiv 2025 (PMC12157518); benchmark tasks available at SNAP-Stanford/Biomni.

BioMate Stable est., Apr 2026

~68–69%

Biomni published Stanford SNAP baseline

65.9%

LABBench — CloningScenarios (Jansen et al., 2025)

What it measures: 33 multiple-choice molecular cloning problems covering restriction enzyme digest, Gibson assembly, Golden Gate assembly, and gRNA spacer design. Requires precise biochemistry knowledge: fragment sizes, overhang sequences, enzyme compatibility. Scale: % correct (4-choice MCQ). Citation: Jansen et al., LABBench: A Challenging Benchmark for AI in Biological Research (2025). The original paper reports evaluation results for foundation LLM baselines (including Claude 3.5 Sonnet); BioMate's score reflects BioMate's own evaluation run against the published LABBench dataset (April 2026).

BioMate

93.9%

Claude 3.5 Sonnet Published baseline

60%

BioMate platform benchmarks (April 2026)

What it measures: Task-specific datasets measuring core execution capabilities: workflow routing accuracy (120 queries, April 2026; exact first-choice with closely-related equivalents accepted), prerequisite parameter auto-recovery, and parameter prefill accuracy. These benchmarks have no published external comparators as they test BioMate-specific features. Scale: % correct per task set.

Workflow routing n=120, exact first-choice

90.8%

Prereq recovery n=80 tasks

97.5%

Parameter prefill n=115 cases

100%

Summary

BioMate AI is a production workflow execution platform with validated performance in ADMET prediction, PBPK modeling, and regulatory document assembly. It is suited for drug discovery teams that need results delivered as audit-ready outputs, including IND sections and CRO packages with GxP compliance alignment.

Claude Science is a research workbench designed for academic and early-stage R&D — useful for analysis, literature synthesis, and manuscript preparation across multiple scientific domains.

Biomni is an open-source research agent capable of handling a broad range of biomedical reasoning tasks without task-specific configuration, making it a flexible tool for exploratory research.

Robin + Finch is a multi-agent system oriented toward autonomous hypothesis-to-validation cycles in drug discovery, with a focus on literature retrieval and omics data analysis.

GPT-5.5 / Rosalind are foundation models that provide strong general biomedical reasoning and can serve as the LLM backbone for custom pipelines and tools.